A

Atea Pharmaceuticals

D
AVIR
USD
-0.035
(-1.0072%)
Market Closed
6,600.00
Volume
EPS
-
Div Yield
-1.638095
P/E
290,411,680.00
Market Cap
Today
-1.0072%
1 Week
6.173%
1 Month
0.880%
6 Months
-12.690%
12 Months
2.381%
Year To Date
12.602%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ADAP
-0.0586
(-7.0585%)
USD
X
XENE
0.76
(1.6908%)
USD
I
ICHR
1.35
(4.1538%)
USD
A
ASND
-2.7
(-2.089%)
USD
C
CRNC
0.04
(1.2618%)
USD
N
NVAX
0.505
(5.8247%)
USD
A
ABUS
-0.195
(-4.9618%)
USD
G
GERN
0.015
(0.3513%)
USD

Title:
Atea Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Do you need help or have a question?
Contact Us